Depotwettbewerb USA 35 KW
Seite 4 von 5 Neuester Beitrag: 25.04.21 13:30 | ||||
Eröffnet am: | 24.08.03 03:40 | von: Eskimato | Anzahl Beiträge: | 112 |
Neuester Beitrag: | 25.04.21 13:30 | von: Jessikaziwda | Leser gesamt: | 14.791 |
Forum: | Börse | Leser heute: | 8 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 | | 5 > |
Nr.7 von 10 fliegt deshalb mit fast unch raus.
FAKTEN:
DKEY KK 0,66 VK 0,68 (27401) = 18633,-
---- -- ---- ------- ------- + 143232 ( aus # 71)
---- -- ---- ------- ------- = 161865 Dollar als Zwischensumme in Cash!
3 Werte (IIIM, MBAY und CRDS) verbleiben noch im Depot!
Bis demnächst Gr.Gr.
TUESDAY, SEPTEMBER 09, 2003 9:30 AM
- BusinessWire
CAMBRIDGE, Mass., Sep 9, 2003 (BUSINESS WIRE) -- SatCon Technology Corporation(C) (NASDAQ NM: SATC), a developer and manufacturer of electronic power control systems, today announced that the Company realized a significant increase in order backlog for the current period. At the end of the Company's fiscal year in September 2002, the backlog totaled $16 million with $13 million shippable in 12 months. At the end of its third quarter in June 2003, backlog totaled $22 million, with $17 million expected to be shipped in the next 12 months, an increase of over 35%.
The current backlog includes contracts for military power control systems, large megawatt sized fuel cell power conversion systems, high reliability defense communications electronics, and high power control systems for commercial applications.
The Company further reports that during its period of restructuring, it has significantly reduced costs, improved its cash position, and at the same time experienced increased order flow for military and defense electronics work. From 2001 to the present, Satcon has received $12 million in U.S. Navy grants to develop an Integrated Power System (IPS) for all-electric ships.
David Eisenhaure, president and chief executive officer, stated: "I am proud of the progress our management team has made over the last nine months. Not only have we cut costs significantly in order to position ourselves for near-term profitability, we have also developed and implemented a plan to generate adequate cash to sustain our progress."
He also added, "Our substantial order backlog is a very positive sign and evidence that our restructuring efforts are working. Also, we believe the national focus on the nation's power grid will create additional opportunities for our unique power generation systems among federal, state and local governments. We believe that Satcon possesses some of the best expertise in the world in areas that can help support the nation's power grid. With a stronger balance sheet, our considerable order backlog, and a more focused and mature product line, we are well-positioned for future growth."
Proxim Outlook: Street Sees 3Q Loss 2 Cents/Share
Tuesday September 9, 5:34 pm ET
SUNNYVALE, Calif. -(Dow Jones)- Proxim Corp. (NasdaqNM:PROX - News) issued third-quarter guidance below Wall Street expectations but said its ongoing restructuring efforts are progressing well.
The company also expanded its relationship with Motorola Inc. (NYSE:MOT - News) .
In a press release Tuesday, the wireless networking equipment company forecast a pro forma loss of 3 cents to 5 cents a share.
Analysts polled by Thomson First Call (News - Websites), on average, expect Proxim to lose 2 cents a share in the third quarter.
Including patent litigation costs, interest expenses on convertible promissory notes and an $11 million restructuring benefit, the company projects a loss of 2 cents to 4 cents a share.
In the third quarter of 2002, Proxim lost 29 cents a share on revenue of $24.1 million.
The company said its restructuring efforts continue to go well, noting that it has cut its facilities to 12 from 20, which includes a drop in the number of research and development centers to two from six.
Weiterer Cash- Aufbau is bei mich angesacht.
Deswegen fliegt die Nr.8 von 10 heute zum SK 09.09.03 raus.
Hatte mir eigentlich auch aufgrund der letzten MBAY- News mehr von der Aktie versprochen.
War zwischenzeitlich auch zu Beginn dieser Runde ma fast 30% damit vorne, aber der Titel konnte es nich halten.
Bin froh bis jetzt alle 8 von 10 mit Plus verscherbelt zu haben, wenngleich meine letzten Absacker mehr einer Nullrunde hingelegt haben.
Am WE (so Eski will) würde ein ganz neues gruenes Depot hier erscheinen.
FAKTEN:
MBAY KK 0,80 SK/VK 0,82 (22606) = 18537
---- -- ---- ----- ---- ------- + 161865 ( aus # 78 )
---- -- ---- ----- ---- ------- = 180402 Dollar als Zwischensumme in Cash!
2 Werte (IIIM und CRDS) verbleiben noch im Depot.
Gr.Gr.
Hatte SATC von 0,60 bis 0,77 und von 0,88 bis 1,05 !
Kleinvieh macht auch Mist, wenngleich ich deutlich unter den Chancen geblieben bin.
Selbst im echten gruenen Depot war es bei SATC ähnlich!
Rudi würde sagen:
- die Spielansätze sind gut durchdacht
- die Steilpässe nach vorn wurden oft richtig gut gespielt
- der Stürmer hat aber aufgrund seiner hippeligen Beine und "Finger" wenig draus gemacht
- er bekommt aber trotzdem im nächsten Spiel nochmal eine Chance
- er soll lernen seine Fähigkeiten richtig umzusetzen
Gr.Gr.;-)
Als alter ARIVA- Fuchs und OTC- Fan wäre sogar ein Fuchsbau- Depot hier sicher gern gesehen.
Wenn du nach regelmäßiger ARIVA- Postig- Auszeit ma Lust hast alle in Grund und Boden zu traden, kannste datt (wenn Eski als Spielleiter) Deiner Zulassung zustimmt auch im Spiel hier gerne tun.
Gekauft wird "nur" zu freitäglichen SK
Depotaufstellung bis Samstag 18:00
Verkauft darf täglich zum SK bzw. am Folgetag bis 12:00 werden
11% Pflicht SL besteht
40 000 Dollar darfste als Ausgangssumme investieren
Wenn wir uns alle zukünftig auf 5 Depotwerte pro Wochenrunde beschränken, ist bestimmt für ein Fuchs- Depot Platz!?!
Wäre echt gespannt, wieviel Dollar du Weihnachten 03 noch zur Verfügung hast.
PS: Im Spiel wie im Leben sind vielleicht viele Jäger Füxleins Tod!
;-)
Die Tipps unter Woche sind hier fürs richtige Börsenleben gern gesehen.
Fürs akt. Spiel finden sie unter den Tagen keine Berücksichtigung.
Na, haste Lust?
Ich wäre dann zur Zeit für dich die Gans!
Gr.Gr.
Ich hatte mal spaßeshalber mein Spieledepot vom 29.5. abgespeichert - das hätte unverändert bis gestern immerhin auch 50% gemacht...
RBAK raus! bestens zum nächstmöglichen zeitpunkt
SL bei BRCD:6,20§ und BRCM 26,90
§
gruss an eskimo eskimato
In den Anfangsrunden waren die von 4,50 bis 5,00 oder so auch im gruenen Depot.
Dutzende weitere Beispiele könnten wir hier nennen.
So ist Börse!
Wer hätte aber auch ernsthaft gedacht, datt die Aktien- Party in 03 so abgeht?
Ich mit Sicherheit nicht, deshalb lieber öfters (nachbetrachtet zu oft) den Spatz auf der Bank als die Taube im Depot.
Hinterher ist man immer schlauer, aber solange die Kurzfristchancen nich abnehmen ....
Irgendwie scheint aber nach einem derartigen Anstieg eine zumindest kleinere Konsolidierung angebracht.
Mag vielleicht auch etwas am 11.09. liegen.
Big- US- Player sehen datt Momentum für diese Woche deshalb eher flat.
Vorhersagen sind freilich fast unmöglich, aber an Zwischen- Gewinnmitnahmen is noch keiner gestorben.
Und watt der September die letzten Jahre für ein Performance- Monat war wissen wir doch alle.
Is denn in 03 alles anders?
Am WE sind wir wieder schlauer.
Re Zufall, du darst deine RBAK zum gestrigen SK verkaufen
Deine anderen Wünsche finden (so sich nix ändert) am WE (Basis Fr. SK)Berücksichtigung
Genaue Angaben zu Verkäufen musst du hier bis 12:00 schon selber übersichtlich anzeigen.
Gr.Gr.
3.500 ATS 2.72 = 9.520,--
3.000 ONT 2.78 = 8.340,--
Zusammen mit Cash aus Pos.70 (DNDN = 8.950,--) Gesamtcash 26.810,--
Bis dann Ciao B.L.
Mal sehen,was morgen passiert.
auf Sectorperform jäh zurückgekommen :-( Fuck the Analysts
CONCURRENT COMPUTER CORP - Nasdaq National Market: CCUR
Consolidated Real-time Market Quote*
Last | Change (%) | After Hours Chg (%)** | Bid | Ask | Trade Time |
4.253 | 0.367 (7.94) | 0.003 (0.07) | 4.01 (10) | 4.55 (3) | 15:59 |
Exchange Quote
Last | Change (%) | Bid (size) | Ask (size) | Trade Time |
4.25 | 0.37 (8.01) | 4.25 (1) | 4.26 (1) | 16:00 |
Day Volume | Last Size | Open | High | Low |
1,309,384 | 2,900 | 4.40 | 4.47 | 4.10 |
Latest Ticks | # of Trades | Avg Trade Size | VWAP | 52 Wk High |
==== | 2,149 | 609 | 4.2518 | 4.34 |
52 Wk Low | Prev Close | Avg Day Vol | ||
1.25 | 4.62 | 1,714,900 |
CCUR hatte ich übrigens auch schon mal vor einiger Zeit in der WL.
CCUR
| |||||||||||||||
Dendreon to Present Promising Results from New Protease Activated Therapy -- PACT -- Program SEATTLE--(BUSINESS WIRE)--Sept. 11, 2003--Dendreon Corporation (Nasdaq:DNDN - News) today announced it will present data on a lead compound from its new Protease Activated Therapy (PACT) therapeutic platform. In preclinical testing to date, the compound, CVS 10290, has demonstrated a significant reduction in tumor volume compared to conventional chemotherapy. The results will be presented by Edwin L. Madison, Ph.D., vice president of biological research at Dendreon, during the Biochemical Society's 57th Harden Conference: Proteinase Structure and Function taking place Sept. 9 to 13 in Oxford, UK. Dendreon's PACT program focuses on exploiting, rather than blocking, the activity of proteases on the surface of tumor cells. The goal of this prodrug approach is to deliver a potent cytotoxic, or cell-killing drug directly to the tumor cells, thereby sparing healthy tissue. Data to be presented demonstrate in preclinical in vivo models of prostate cancer that CVS 10290 produced an approximately 85 percent reduction in tumor growth compared to conventional chemotherapy (p=0.0008). In addition, CVS 10290 was shown to have a considerably better safety profile than conventional chemotherapy, with no morbidity related to toxicity, as compared to 30 percent morbidity for conventional chemotherapy, and reduced chemotherapy-associated side effects. Additional studies with CVS 10290 demonstrated similar results in breast cancer models. PACT involves the design of synthetic molecules composed of a sequence of amino acids that are selectively recognized by a targeted, cancer-associated serine protease. This peptide is chemically attached to a known cancer chemotherapeutic or cytotoxic drug, yielding a hybrid or conjugate molecule. This highly targeted approach is expected to reduce damage to normal, non-tumor cells because the sequence of attached amino acids delivers the cytotoxic agent directly to tumor cells. "This study supports the role of this new and exciting class of drugs for cancer therapy that offers the potential for not only enhanced efficacy but reduced side effects as well," said Reiner Laus, M.D., vice president of research and development at Dendreon. "We look forward to advancing our first PACT compound into clinical development and expanding Dendreon's platform technologies in oncology." Dendreon Corporation is a biotechnology company developing targeted therapies for cancer. The company's lead investigational product candidate, Provenge®, is a cancer immunotherapy undergoing a pivotal Phase 3 clinical trial for the potential treatment of androgen independent prostate cancer. In addition to its immunotherapies in clinical and preclinical development for a variety of cancers, Dendreon's product pipeline also includes monoclonal antibody, small molecule and prodrug product candidates. Dendreon has research and development alliances with Genentech, Inc., Kirin Brewery Co., Ltd., Abgenix, Inc. and Dyax Corp. For more information about the company and its programs, visit www.dendreon.com. Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include risks that the safety and/or efficacy results of preclinical studies will not support further development, risks associated with development of early stage product candidates through preclinical and clinical research and development, risks associated with completing Dendreon's clinical trials, the risks that the safety and/or efficacy results of a clinical trial will not support an application for a biologics license, the risk that the FDA will not approve a product for which a biologics license has been applied, the uncertainty of Dendreon's future access to capital, risks relating to Dendreon's relatively limited operating history, the failure by Dendreon to secure and maintain relationships with collaborators, the dependence on the efforts of third parties, the risks that a patent will not be granted or that the claims will be restricted or challenged by a third party, and the dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations, are contained in Dendreon's SEC reports, which are available at www.sec.gov Contact: Dendreon Corporation |